Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 10/20 | 0.69 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1238284 | 0.99 | KCNA5 (0.68) | KCNA5NAMPTGRM2CHRM2KCNJ5 | |
| SCHEMBL1239156 | 0.99 | KCNA5 (0.68) | KCNA5NAMPTGRM2CHRM2KCNJ5 | |
| SCHEMBL1237165 | 0.96 | KCNA5 (0.66) | KCNA5NAMPTGRM2KCNJ5KCNJ3 | |
| SCHEMBL1239837 | 0.93 | KCNA5 (0.65) | KCNA5NAMPTGRM2KCNJ5KCNJ3 | |
| SCHEMBL12080668 | 0.91 | KCNA5 (0.70) | KCNA5NAMPTCHRM2CYP1A2CYP3A4 | |
| SCHEMBL1239365 | 0.90 | KCNA5 (0.69) | KCNA5NAMPTCHRM2CYP1A2CYP3A4 | |
| SCHEMBL15986302 | 0.87 | KCNA5 (0.67) | KCNA5NAMPTCHRM2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL12080656 | 0.87 | KCNA5 (0.61) | KCNA5NAMPTCHRM2KCNJ5KCNJ3 | |
| SCHEMBL1238479 | 0.84 | KCNA5 (0.66) | KCNA5NAMPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1239784 | 0.84 | KCNA5 (0.58) | KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARCACEUTICAL CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARMA CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-8822453-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2746272-A1 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-20120225866-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2467364-A2 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011021726-A2 | NITROGEN-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | KCNA5 9/4885NAMPT 3299/4885GRM2 1048/4885 |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | KCNA5 9/4885NAMPT 3299/4885GRM2 1048/4885 |
| US-20120225866-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | KCNA5 9/4885NAMPT 3299/4885GRM2 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.